

MATERIALS LICENSE  
SUPPLEMENTARY SHEET

License number

09-04233-03

Docket or Reference number

030-01345

Amendment No. 38

VA Medical Center  
Bay Pines, Florida 33504

In accordance with letter dated July 1, 1985, License Number 09-04233-03 is amended as follows:

Items 6, 7, 8, and 9 are amended to read:

- |  |  |  |
|--|--|--|
| A. Any byproduct material listed in Groups I and II of Schedule A, Section 35.100 of 10 CFR 35 | A. Any radio-pharmaceutical listed in Groups I and II of Schedule A, Section 35.100 of 10 CFR 35 | A. As necessary for uses authorized in Subitem 9.A.                    |
| B. Any byproduct material listed in Group III of Schedule A, Section 35.100 of 10 CFR 35       | B. Any form listed in Group III of Schedule A, Section 35.100 of 10 CFR 35                       | B. 8 curies of each byproduct material authorized in Subitem 6.B.      |
| C. Any byproduct material listed in Group IV of Schedule A, Section 35.100 of 10 CFR 35        | C. Any radio-pharmaceutical listed in Group IV of Schedule A, Section 35.100 of 10 CFR 35        | C. As necessary for uses authorized in Subitem 9.C.                    |
| D. Any byproduct material listed in Group V of Schedule A, Section 35.100 of 10 CFR 35         | D. Any radio-pharmaceutical listed in Group V of Schedule A, Section 35.100 of 10 CFR 35         | D. As necessary for uses authorized in Subitem 9.D.                    |
| E. Any byproduct material listed in Section 31.11(a) of 10 CFR 31                              | E. Any   | E. 5 millicuries of each byproduct material authorized in Subitem 6.E. |

8509250386 850813  
REG2 LIC30  
09-04233-03 PDRML 20  
11

MATERIALS LICENSE  
SUPPLEMENTARY SHEET

License number

09-04233-03

Docket or Reference number

030-01345

Amendment No. 38

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
F. Xenon 133	F. Gas or gas in solution that is the subject of an active (i.e., not withdrawn or terminated) "New Drug Application" (NDA) approved by FDA or an active (i.e., not withdrawn, terminated or on "clinical hold") "Notice of Claimed Investigational Exemption for a New Drug" (IND) that has been accepted by FDA.	F. 500 millicuries
G. Iodine 125	G. Sealed source (AECL Model C-235 or C-236)	G. sources of 200 millicuries each, 400 millicuries total.
H. Hydrogen 3	H. Labelled compounds	H. 6 millicuries
I. Carbon 14	I. Labelled compounds	I. 6 millicuries
J. Zinc 65	J. Any	J. 2 millicuries
K. Calcium 45	K. Any	K. 2 millicuries
L. Calcium 47	L. Any	L. 2 millicuries
M. Copper 64	M. Any	M. 2 millicuries
N. Copper 67	N. Any	N. 2 millicuries
O. Chromium 51	O. Any	O. 2 millicuries
P. Iodine 125	P. Any	P. 2 millicuries
Q. Iodine 131	Q. Any	Q. 2 millicuries
R. Cadmium 109	R. Any	R. 2 millicuries

MATERIALS LICENSE  
SUPPLEMENTARY SHEET

License number

09-04233-03

Docket or Reference number

030-01345

Amendment No. 38

- |   |                                  |  |
|---|----------------------------------|--|
| 6. Byproduct, source, and/or special nuclear material | 7. Chemical and/or physical form | 8. Maximum amount that licensee may possess at any one time under this license |
| S. Nickel 63  | S. Any                           | S. 2 millicuries   |
| T. Selenium 75  | T. Any                           | T. 1 millicurie  |
| U. Tin 113  | U. Any                           | U. 1 millicurie  |
9. Authorized use
- A. Any diagnostic procedure listed in Groups I and II of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.
  - B. Preparation and use of radiopharmaceuticals for any diagnostic procedure listed in Group III of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.
  - C. Any therapeutic procedure listed in Group IV of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.
  - D. Any therapeutic procedure listed in Group V of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.
  - E. In vitro studies.
  - F. For blood flow and pulmonary function studies.
  - G. For human use in a Norland Model N2740 Bone Densitometer for bone mineral analysis.
  - H. through U. For use in animal studies.

Condition 12 is amended to read:

12. Licensed material listed in Item 6 above is authorized for use by, or under the supervision of, the following individual(s) for the materials and uses indicated:

Rafael Abadal, M.D.

Carbon 14 for animal studies

Steven Harwood, M.D.

Groups I, II, III, IV and V

In vitro studies

Xenon 133

Iodine 125 in Norland Bone Densitometer

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License number  
09-04233-03

Docket or Reference number  
030-01345

Amendment No. 38

Robert G. Carroll, M.D.

Groups I, II, III, IV and V

In vitro studies

Xenon 133

Hydrogen 3 and Carbon 14 for animal studies

Iodine 125 in Norland Bone Densitometer

Harvey V. Samis, Ph.D.

Hydrogen 3 and Carbon 14 for animal studies

Edward A. Eikman, M.D.

Groups I, II, III, IV and V

In vitro studies

Xenon 133

Hydrogen 3 and Carbon 14 for animal studies

Arthur B. Chausmer, M.D.

In vitro studies

Items 6.H through 6.U for animal studies

Iodine 125 in Norland Bone Densitometer

Stanley Wallach, M.D.

In vitro studies


Iodine 125 in Norland Bone Densitometer

Abdul-Hamid Ismail Hakki, M.D.

Technetium 99m for cardiac diagnostic studies

Levy Kopelovich, Ph.D.

In vitro studies



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date AUG 13 1985

By PAUL R. GUINN  
*Paul R. Guinn*  
Region II, Nuclear Materials  
Safety Section  
101 Marietta Street, Suite 2900  
Atlanta, GA 30323